AGENT FOR PREVENTING AND/OR TREATING BLOOD CANCER
To provide novel formulations having anti-blood cancer action and having few side effects.SOLUTION: Provided is a prophylactic and/or therapeutic agent for blood cancer, comprising luseogliflozin. In the present invention, luseogliflozin can suppress the growth of blood cancer cells and enables the...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; jpn |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | NAKACHI SAWAKO TAMAKI KEITA MASUZAKI HIROAKI NISHI YUKIKO OKAMOTO SHIKI MORICHIKA KAZUHO YONAMINE MASATO MORISHIMA SATOKO NOMURA IKUMI |
| description | To provide novel formulations having anti-blood cancer action and having few side effects.SOLUTION: Provided is a prophylactic and/or therapeutic agent for blood cancer, comprising luseogliflozin. In the present invention, luseogliflozin can suppress the growth of blood cancer cells and enables the range of cancer treatment options to be expanded by being used in the prevention and/or treatment of blood cancers. In addition, such drugs can be used as safe therapeutics with few side effects and can be a drug having a novel action different from conventional anti-blood cancer therapeutic agents. Furthermore, it has been suggested that the use of luseogliflozin in combination with conventionally used anticancer drugs has a therapeutic enhancement effect, and it is very useful in that it can provide a new treatment method.SELECTED DRAWING: Figure 7
【課題】抗血液がん作用を有し、副作用が少ない新たな製剤を提供すること。【解決手段】ルセオグリフロジンを含有することを特徴とする血液がんの予防及び／又は治療剤。本発明において、ルセオグリフロジンは血液がん細胞の増殖を抑制することができ、血液がんの予防及び／又は治療に用いることで、がん治療の選択の幅を広げることが可能となる。また、かかる薬剤は副作用の少ない安全な治療薬として用いることができ、従来の抗血液がん治療剤とは異なる新たな作用を有する薬剤となり得る。さらに、従来から用いられている抗がん剤に対し、ルセオグリフロジンを併用することで、治療増強効果を有することが示唆され、新たな治療方法を提供可能な点で、非常に有用である。【選択図】図７ |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_JP2020045319A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JP2020045319A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_JP2020045319A3</originalsourceid><addsrcrecordid>eNrjZDB0dHf1C1Fw8w9SCAhyDQOyPf3cFRz9XPSBIiFBro5gvpOPv7-LgrOjn7NrEA8Da1piTnEqL5TmZlBycw1x9tBNLciPTy0uSExOzUstifcKMDIwMjAwMTU2tHQ0JkoRAIOrJrU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>AGENT FOR PREVENTING AND/OR TREATING BLOOD CANCER</title><source>esp@cenet</source><creator>NAKACHI SAWAKO ; TAMAKI KEITA ; MASUZAKI HIROAKI ; NISHI YUKIKO ; OKAMOTO SHIKI ; MORICHIKA KAZUHO ; YONAMINE MASATO ; MORISHIMA SATOKO ; NOMURA IKUMI</creator><creatorcontrib>NAKACHI SAWAKO ; TAMAKI KEITA ; MASUZAKI HIROAKI ; NISHI YUKIKO ; OKAMOTO SHIKI ; MORICHIKA KAZUHO ; YONAMINE MASATO ; MORISHIMA SATOKO ; NOMURA IKUMI</creatorcontrib><description>To provide novel formulations having anti-blood cancer action and having few side effects.SOLUTION: Provided is a prophylactic and/or therapeutic agent for blood cancer, comprising luseogliflozin. In the present invention, luseogliflozin can suppress the growth of blood cancer cells and enables the range of cancer treatment options to be expanded by being used in the prevention and/or treatment of blood cancers. In addition, such drugs can be used as safe therapeutics with few side effects and can be a drug having a novel action different from conventional anti-blood cancer therapeutic agents. Furthermore, it has been suggested that the use of luseogliflozin in combination with conventionally used anticancer drugs has a therapeutic enhancement effect, and it is very useful in that it can provide a new treatment method.SELECTED DRAWING: Figure 7
【課題】抗血液がん作用を有し、副作用が少ない新たな製剤を提供すること。【解決手段】ルセオグリフロジンを含有することを特徴とする血液がんの予防及び／又は治療剤。本発明において、ルセオグリフロジンは血液がん細胞の増殖を抑制することができ、血液がんの予防及び／又は治療に用いることで、がん治療の選択の幅を広げることが可能となる。また、かかる薬剤は副作用の少ない安全な治療薬として用いることができ、従来の抗血液がん治療剤とは異なる新たな作用を有する薬剤となり得る。さらに、従来から用いられている抗がん剤に対し、ルセオグリフロジンを併用することで、治療増強効果を有することが示唆され、新たな治療方法を提供可能な点で、非常に有用である。【選択図】図７</description><language>eng ; jpn</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2020</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200326&DB=EPODOC&CC=JP&NR=2020045319A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200326&DB=EPODOC&CC=JP&NR=2020045319A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>NAKACHI SAWAKO</creatorcontrib><creatorcontrib>TAMAKI KEITA</creatorcontrib><creatorcontrib>MASUZAKI HIROAKI</creatorcontrib><creatorcontrib>NISHI YUKIKO</creatorcontrib><creatorcontrib>OKAMOTO SHIKI</creatorcontrib><creatorcontrib>MORICHIKA KAZUHO</creatorcontrib><creatorcontrib>YONAMINE MASATO</creatorcontrib><creatorcontrib>MORISHIMA SATOKO</creatorcontrib><creatorcontrib>NOMURA IKUMI</creatorcontrib><title>AGENT FOR PREVENTING AND/OR TREATING BLOOD CANCER</title><description>To provide novel formulations having anti-blood cancer action and having few side effects.SOLUTION: Provided is a prophylactic and/or therapeutic agent for blood cancer, comprising luseogliflozin. In the present invention, luseogliflozin can suppress the growth of blood cancer cells and enables the range of cancer treatment options to be expanded by being used in the prevention and/or treatment of blood cancers. In addition, such drugs can be used as safe therapeutics with few side effects and can be a drug having a novel action different from conventional anti-blood cancer therapeutic agents. Furthermore, it has been suggested that the use of luseogliflozin in combination with conventionally used anticancer drugs has a therapeutic enhancement effect, and it is very useful in that it can provide a new treatment method.SELECTED DRAWING: Figure 7
【課題】抗血液がん作用を有し、副作用が少ない新たな製剤を提供すること。【解決手段】ルセオグリフロジンを含有することを特徴とする血液がんの予防及び／又は治療剤。本発明において、ルセオグリフロジンは血液がん細胞の増殖を抑制することができ、血液がんの予防及び／又は治療に用いることで、がん治療の選択の幅を広げることが可能となる。また、かかる薬剤は副作用の少ない安全な治療薬として用いることができ、従来の抗血液がん治療剤とは異なる新たな作用を有する薬剤となり得る。さらに、従来から用いられている抗がん剤に対し、ルセオグリフロジンを併用することで、治療増強効果を有することが示唆され、新たな治療方法を提供可能な点で、非常に有用である。【選択図】図７</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2020</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDB0dHf1C1Fw8w9SCAhyDQOyPf3cFRz9XPSBIiFBro5gvpOPv7-LgrOjn7NrEA8Da1piTnEqL5TmZlBycw1x9tBNLciPTy0uSExOzUstifcKMDIwMjAwMTU2tHQ0JkoRAIOrJrU</recordid><startdate>20200326</startdate><enddate>20200326</enddate><creator>NAKACHI SAWAKO</creator><creator>TAMAKI KEITA</creator><creator>MASUZAKI HIROAKI</creator><creator>NISHI YUKIKO</creator><creator>OKAMOTO SHIKI</creator><creator>MORICHIKA KAZUHO</creator><creator>YONAMINE MASATO</creator><creator>MORISHIMA SATOKO</creator><creator>NOMURA IKUMI</creator><scope>EVB</scope></search><sort><creationdate>20200326</creationdate><title>AGENT FOR PREVENTING AND/OR TREATING BLOOD CANCER</title><author>NAKACHI SAWAKO ; TAMAKI KEITA ; MASUZAKI HIROAKI ; NISHI YUKIKO ; OKAMOTO SHIKI ; MORICHIKA KAZUHO ; YONAMINE MASATO ; MORISHIMA SATOKO ; NOMURA IKUMI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_JP2020045319A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; jpn</language><creationdate>2020</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>NAKACHI SAWAKO</creatorcontrib><creatorcontrib>TAMAKI KEITA</creatorcontrib><creatorcontrib>MASUZAKI HIROAKI</creatorcontrib><creatorcontrib>NISHI YUKIKO</creatorcontrib><creatorcontrib>OKAMOTO SHIKI</creatorcontrib><creatorcontrib>MORICHIKA KAZUHO</creatorcontrib><creatorcontrib>YONAMINE MASATO</creatorcontrib><creatorcontrib>MORISHIMA SATOKO</creatorcontrib><creatorcontrib>NOMURA IKUMI</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>NAKACHI SAWAKO</au><au>TAMAKI KEITA</au><au>MASUZAKI HIROAKI</au><au>NISHI YUKIKO</au><au>OKAMOTO SHIKI</au><au>MORICHIKA KAZUHO</au><au>YONAMINE MASATO</au><au>MORISHIMA SATOKO</au><au>NOMURA IKUMI</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>AGENT FOR PREVENTING AND/OR TREATING BLOOD CANCER</title><date>2020-03-26</date><risdate>2020</risdate><abstract>To provide novel formulations having anti-blood cancer action and having few side effects.SOLUTION: Provided is a prophylactic and/or therapeutic agent for blood cancer, comprising luseogliflozin. In the present invention, luseogliflozin can suppress the growth of blood cancer cells and enables the range of cancer treatment options to be expanded by being used in the prevention and/or treatment of blood cancers. In addition, such drugs can be used as safe therapeutics with few side effects and can be a drug having a novel action different from conventional anti-blood cancer therapeutic agents. Furthermore, it has been suggested that the use of luseogliflozin in combination with conventionally used anticancer drugs has a therapeutic enhancement effect, and it is very useful in that it can provide a new treatment method.SELECTED DRAWING: Figure 7
【課題】抗血液がん作用を有し、副作用が少ない新たな製剤を提供すること。【解決手段】ルセオグリフロジンを含有することを特徴とする血液がんの予防及び／又は治療剤。本発明において、ルセオグリフロジンは血液がん細胞の増殖を抑制することができ、血液がんの予防及び／又は治療に用いることで、がん治療の選択の幅を広げることが可能となる。また、かかる薬剤は副作用の少ない安全な治療薬として用いることができ、従来の抗血液がん治療剤とは異なる新たな作用を有する薬剤となり得る。さらに、従来から用いられている抗がん剤に対し、ルセオグリフロジンを併用することで、治療増強効果を有することが示唆され、新たな治療方法を提供可能な点で、非常に有用である。【選択図】図７</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; jpn |
| recordid | cdi_epo_espacenet_JP2020045319A |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | AGENT FOR PREVENTING AND/OR TREATING BLOOD CANCER |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T08%3A50%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=NAKACHI%20SAWAKO&rft.date=2020-03-26&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EJP2020045319A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |